Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received three drug license suspension orders from state drug control authorities. The suspensions affect stores at Medplus Main Road (Ieeja village, Telangana – 3 days), Surampatti Nall Road (Tamil Nadu – 3 days), and New Maruthi Nagar Kothapet (Telangana – 1 day). The orders were received on May 23, 2025, issued under Rule 65 of the Drugs and Cosmetics Act, 1940. The combined potential revenue loss from these suspensions is approximately Rs 1.55 lakhs. The company has disclosed this under SEBI Listing Regulations to maintain transparency with investors.
The financial impact is negligible at roughly Rs 1.55 lakhs in potential revenue across just three stores out of Medplus's large network. This is a routine regulatory disclosure and is unlikely to have any meaningful effect on the stock price or overall business operations.